Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL6 | P05231 | 8/20 | 0.62 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.37 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4134498 | 0.92 | IL6 (0.61) | IL6NTRK1NTRK3BRD4BACE1 | |
| SCHEMBL4581099 | 0.91 | IL6 (0.59) | IL6NTRK1NTRK3BRD4ALDH1A1 | |
| SCHEMBL4580913 | 0.86 | IL6 (0.62) | IL6NTRK1APOBEC3AAPOBEC3GALDH1A1 | |
| SCHEMBL4581415 | 0.86 | IL6 (0.72) | IL6SMN1; SMN2APOBEC3AAPOBEC3GALDH1A1 | |
| SCHEMBL4132723 | 0.85 | IL6 (0.59) | IL6SMN1; SMN2APOBEC3AAPOBEC3GL3MBTL1 | |
| SCHEMBL4140024 | 0.84 | IL6 (0.63) | IL6ALDH1A1NR3C1PGR | |
| SCHEMBL4141693 | 0.84 | IL6 (0.45) | IL6NTRK1NTRK3SMN1; SMN2HTT | |
| SCHEMBL4581420 | 0.83 | IL6 (0.54) | IL6SMN1; SMN2APOBEC3AAPOBEC3GL3MBTL1 | |
| SCHEMBL4591114 | 0.83 | IL6 (0.65) | IL6SMN1; SMN2APOBEC3AAPOBEC3GALDH1A1 | |
| SCHEMBL16556371 | 0.82 | IL6 (0.57) | IL6NTRK1SMN1; SMN2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975256-B2 | 1,2,3,4-tetrahydroquinoxaline compounds having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2015-03-10 | — | — | US | disclosed |
| US-8975256-B2 | 1,2,3,4-tetrahydroquinoxaline compounds having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2015-03-10 | — | — | US | disclosed |
| US-8975256-B2 | 1,2,3,4-tetrahydroquinoxaline compounds having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2015-03-10 | — | — | US | disclosed |
| US-20130303537-A1 | 1,2,3,4-TETRAHYDROQUINOXALINE COMPOUNDS HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-11-14 | — | — | US | disclosed |
| US-8551991-B2 | 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| US-8551991-B2 | 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-1995242-B1 | NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-11-07 | — | — | EP | disclosed |
| EP-1995242-B1 | NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-20090111807-A1 | Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20090111807-A1 | Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| EP-1995242-A1 | NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | Santen Pharmaceutical Co., Ltd (JP) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303537-A1 | 1,2,3,4-TETRAHYDROQUINOXALINE COMPOUNDS HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | NR3C1, NR3C2, NR5A1 | IL6 3798/4885NTRK1 507/4885NTRK3 1147/4885 |
| US-20090111807-A1 | Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity | NR3C1, NR3C2, MC2R | IL6 3728/4885NTRK1 592/4885NTRK3 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.